Skip to Main Content

Author Details

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
2013
43
17
PMIDPaper TitleJournal TitlePublished Year
37509723Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.Biomedicines2023
34783071Clinical and genomic features of SPOP-mutant prostate cancer.Prostate2022
35027313Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.Clin Genitourin Cancer2022
35078711Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.Clin Genitourin Cancer2022
32536574Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.Eur Urol Oncol2021
33556233Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.BJU Int2021
33886851Quality of life and long-term outcomes after hospitalization for COVID-19: Protocol for a prospective cohort study (Coalition VII).Rev Bras Ter Intensiva2021
33989272New approaches to targeting the androgen receptor pathway in prostate cancer.Clin Adv Hematol Oncol2021
33955569Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.Prostate2021
33452039Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.J Nucl Med2021
33423945A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.Eur Urol Oncol2021
33215787Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.Oncologist2021
33419682The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Eur Urol2021
33003959The development of apalutamide for the treatment of prostate cancer.Expert Opin Drug Discov2021
32935617Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.J Urol2021
31176623Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Eur Urol2020
31971495Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.J Urol2020
31829450Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.Cancer2020
32634759Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.Eur J Cancer2020
32624276Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.Eur Urol2020
32583330Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.Pathol Oncol Res2020
32462107<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.JCO Precis Oncol2020
30337059Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.Eur Urol2019
31921344Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?Ecancermedicalscience2019
31650100Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.JCO Precis Oncol2019
31389628Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.Prostate2019
31361358A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.Prostate2019
30293905Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.Eur Urol2019
29368341Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.Prostate2018
30188787There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.J Clin Oncol2018
30118330Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.Expert Opin Investig Drugs2018
30199304Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.J Glob Oncol2018
29847851Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.Oncology (Williston Park)2018
29756867Strong Neutron Pairing in core+4n Nuclei.Phys Rev Lett2018
29641940PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.Expert Rev Clin Pharmacol2018
29481189Quasifree (p, 2p) Reactions on Oxygen Isotopes: Observation of Isospin Independence of the Reduced Single-Particle Strength.Phys Rev Lett2018
28717693Pulmonary Nodules in Patients With Nonpulmonary Cancer: Not Always Metastases.J Glob Oncol2016
22670062A shocking hematuria.QJM2015
26568544Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma.Hematol Oncol Clin North Am2015
26474528Lots of steroids and vitamins, tons of complications. Hypercalcemia and nephrocalcinosis as important complications of performance-enhancing drugs.Nefrologia2015
25850579Targeting the immune system in head and neck cancer.Curr Opin Oncol2015
25993150Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.Am Soc Clin Oncol Educ Book2015
24316901Bullous systemic lupus erythematosus in a pregnant woman: a case report.Rev Bras Reumatol2013
  • 1 - 43 of 43

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 6
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Career Start Year 2013
Number of shared co-authors 8
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 23
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 7
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 4
Roberta Ferraldeschi
Astex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 8
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 25
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 13
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 19
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 13
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 12
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 16
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 26
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 22
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 12
Johann S de Bono
The Institute for Cancer Research
Career Start Year 1999
Number of shared co-authors 20
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 15
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 7
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 25
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 12
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 13
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 11
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 18
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 15
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 16
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 18
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 19
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 22
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 19
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 17

Collaborators

Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 19
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 10
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 8
Neeraj Agarwal
Co-authored papers 7
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 7
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 6
Jure Murgic
University Hospital Center Sestre Milosrdnice
Co-authored papers 5
Matthew D Galsky
Co-authored papers 5
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 5
Channing J Paller
Johns Hopkins University School of Medicine
Co-authored papers 4
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 3
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 3
Ryan Phillips
Johns Hopkins University
Co-authored papers 2
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 2
Bradley J Stish
Mayo Clinic
Co-authored papers 2
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 2
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 2
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 2
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 2
Alan H Bryce
Mayo Clinic
Co-authored papers 2
Neil B Desai
University of Texas Southwestern Medical Center
Co-authored papers 1
Inge M van Oort
Radboud University Medical Center
Co-authored papers 1
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 1
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Neil R Parikh
San Antonio Cancer Center
Co-authored papers 1
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers 1
Maha Hussain
Northwestern University
Co-authored papers 1
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Co-authored papers 1
Release 1.2